Clinical Trial Update: An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors [Phase 1, Phase 2]

View source ↗

Summary

Open-label, single-center Phase 1/2 clinical trial evaluating combining surufatinib with temozolomide and S-1 as first-line therapy for advanced neuroendocrine …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• S-1 (tegafur/gimeracil/oteracil)
• Surufatinib (Surufatinib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Neuroendocrine Tumors | Phase 1, Phase 2 | Status: RECRUITING